Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.
Identifieur interne : 000968 ( Main/Exploration ); précédent : 000967; suivant : 000969Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.
Auteurs : Danuta M. Skowronski [Canada] ; Barbara Strauss ; Perry Kendall ; Bernard Duval ; Gaston De SerresSource :
- CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne [ 0820-3946 ] ; 2002.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Vaccins antigrippaux.
- épidémiologie : Canada.
- étiologie : Maladies de l'appareil respiratoire, Maladies de l'oeil.
- Adulte d'âge moyen, Collecte de données, Facteurs de risque, Humains, Récidive, Sujet âgé, Syndrome.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- geographic , epidemiology : Canada.
- etiology : Eye Diseases, Respiratory Tract Diseases.
- Aged, Data Collection, Humans, Middle Aged, Recurrence, Risk Factors, Syndrome.
Abstract
BACKGROUND
During the 2000-2001 influenza vaccination season, a new adverse event associated with the influenza vaccine, called oculorespiratory syndrome (ORS), was identified in Canada. We examined the risk of recurrence of ORS for individuals affected in 2000-2001 who were revaccinated in the community setting in 2001-2002.
METHODS
We conducted a telephone survey in May 2002 in which participants were asked whether they had been revaccinated in the 2001-2002 immunization season and whether they had experienced any recurrence of ORS or any other adverse event. Eligible individuals (n = 609) included residents of British Columbia aged 18 years or more who had reported any type of adverse event associated with the influenza vaccine in 2000 and who had participated in a survey in September 2001 that characterized their adverse event experience.
RESULTS
The response rate to this survey was 92% (561 of 609 people approached). Of the 561 participants, 202 were revaccinated in 2001. Among the 202 revaccinated, 122 individuals had previously reported ORS in 2000: 40 had described their ORS experience in 2000 as mild (present but not bothersome), 44 as moderate (interrupting daily activities), 35 as severe (preventing daily activities) and 3 did not provide specific details. Six of the 122 individuals experienced a recurrence of ORS following revaccination. The estimated risk of recurrence for ORS following revaccination in the community setting was 5% (95% confidence interval 2.2%-10.5%). Four of the 6 individuals described their ORS recurrence in 2001 as milder than the ORS they had experienced in 2000.
INTERPRETATION
We found a low risk of recurrence of ORS for individuals previously affected in 2000 when they were revaccinated in 2001, including those whose ORS in 2000 had prevented daily activities but was not clinically severe. Health care providers should be confident in the safety of recommending revaccination of these individuals. As with all vaccines, however, a detailed risk-benefit assessment should be undertaken before revaccination of people whose previous adverse event experience may have included collapse, respiratory difficulty (including throat tightness) and/or chest discomfort requiring emergency intervention.
PubMed: 12406942
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><nlm:affiliation>UBC Centre for Disease Control, Vancouver, BC. danuta.skowronski@bccdc.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Strauss, Barbara" sort="Strauss, Barbara" uniqKey="Strauss B" first="Barbara" last="Strauss">Barbara Strauss</name></author><author><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name></author><author><name sortKey="Duval, Bernard" sort="Duval, Bernard" uniqKey="Duval B" first="Bernard" last="Duval">Bernard Duval</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12406942</idno><idno type="pmid">12406942</idno><idno type="wicri:Area/Main/Corpus">000A35</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A35</idno><idno type="wicri:Area/Main/Curation">000A35</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A35</idno><idno type="wicri:Area/Main/Exploration">000A35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><nlm:affiliation>UBC Centre for Disease Control, Vancouver, BC. danuta.skowronski@bccdc.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Strauss, Barbara" sort="Strauss, Barbara" uniqKey="Strauss B" first="Barbara" last="Strauss">Barbara Strauss</name></author><author><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name></author><author><name sortKey="Duval, Bernard" sort="Duval, Bernard" uniqKey="Duval B" first="Bernard" last="Duval">Bernard Duval</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author></analytic><series><title level="j">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</title><idno type="ISSN">0820-3946</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Canada (epidemiology)</term><term>Data Collection</term><term>Eye Diseases (etiology)</term><term>Humans</term><term>Influenza Vaccines (adverse effects)</term><term>Middle Aged</term><term>Recurrence</term><term>Respiratory Tract Diseases (etiology)</term><term>Risk Factors</term><term>Syndrome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Canada (épidémiologie)</term><term>Collecte de données</term><term>Facteurs de risque</term><term>Humains</term><term>Maladies de l'appareil respiratoire (étiologie)</term><term>Maladies de l'oeil (étiologie)</term><term>Récidive</term><term>Sujet âgé</term><term>Syndrome</term><term>Vaccins antigrippaux (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Eye Diseases</term><term>Respiratory Tract Diseases</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Maladies de l'appareil respiratoire</term><term>Maladies de l'oeil</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Data Collection</term><term>Humans</term><term>Middle Aged</term><term>Recurrence</term><term>Risk Factors</term><term>Syndrome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Collecte de données</term><term>Facteurs de risque</term><term>Humains</term><term>Récidive</term><term>Sujet âgé</term><term>Syndrome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>During the 2000-2001 influenza vaccination season, a new adverse event associated with the influenza vaccine, called oculorespiratory syndrome (ORS), was identified in Canada. We examined the risk of recurrence of ORS for individuals affected in 2000-2001 who were revaccinated in the community setting in 2001-2002.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We conducted a telephone survey in May 2002 in which participants were asked whether they had been revaccinated in the 2001-2002 immunization season and whether they had experienced any recurrence of ORS or any other adverse event. Eligible individuals (n = 609) included residents of British Columbia aged 18 years or more who had reported any type of adverse event associated with the influenza vaccine in 2000 and who had participated in a survey in September 2001 that characterized their adverse event experience.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The response rate to this survey was 92% (561 of 609 people approached). Of the 561 participants, 202 were revaccinated in 2001. Among the 202 revaccinated, 122 individuals had previously reported ORS in 2000: 40 had described their ORS experience in 2000 as mild (present but not bothersome), 44 as moderate (interrupting daily activities), 35 as severe (preventing daily activities) and 3 did not provide specific details. Six of the 122 individuals experienced a recurrence of ORS following revaccination. The estimated risk of recurrence for ORS following revaccination in the community setting was 5% (95% confidence interval 2.2%-10.5%). Four of the 6 individuals described their ORS recurrence in 2001 as milder than the ORS they had experienced in 2000.</p></div><div type="abstract" xml:lang="en"><p><b>INTERPRETATION</b></p><p>We found a low risk of recurrence of ORS for individuals previously affected in 2000 when they were revaccinated in 2001, including those whose ORS in 2000 had prevented daily activities but was not clinically severe. Health care providers should be confident in the safety of recommending revaccination of these individuals. As with all vaccines, however, a detailed risk-benefit assessment should be undertaken before revaccination of people whose previous adverse event experience may have included collapse, respiratory difficulty (including throat tightness) and/or chest discomfort requiring emergency intervention.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12406942</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0820-3946</ISSN><JournalIssue CitedMedium="Print"><Volume>167</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.</ArticleTitle><Pagination><MedlinePgn>853-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During the 2000-2001 influenza vaccination season, a new adverse event associated with the influenza vaccine, called oculorespiratory syndrome (ORS), was identified in Canada. We examined the risk of recurrence of ORS for individuals affected in 2000-2001 who were revaccinated in the community setting in 2001-2002.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a telephone survey in May 2002 in which participants were asked whether they had been revaccinated in the 2001-2002 immunization season and whether they had experienced any recurrence of ORS or any other adverse event. Eligible individuals (n = 609) included residents of British Columbia aged 18 years or more who had reported any type of adverse event associated with the influenza vaccine in 2000 and who had participated in a survey in September 2001 that characterized their adverse event experience.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The response rate to this survey was 92% (561 of 609 people approached). Of the 561 participants, 202 were revaccinated in 2001. Among the 202 revaccinated, 122 individuals had previously reported ORS in 2000: 40 had described their ORS experience in 2000 as mild (present but not bothersome), 44 as moderate (interrupting daily activities), 35 as severe (preventing daily activities) and 3 did not provide specific details. Six of the 122 individuals experienced a recurrence of ORS following revaccination. The estimated risk of recurrence for ORS following revaccination in the community setting was 5% (95% confidence interval 2.2%-10.5%). Four of the 6 individuals described their ORS recurrence in 2001 as milder than the ORS they had experienced in 2000.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We found a low risk of recurrence of ORS for individuals previously affected in 2000 when they were revaccinated in 2001, including those whose ORS in 2000 had prevented daily activities but was not clinically severe. Health care providers should be confident in the safety of recommending revaccination of these individuals. As with all vaccines, however, a detailed risk-benefit assessment should be undertaken before revaccination of people whose previous adverse event experience may have included collapse, respiratory difficulty (including throat tightness) and/or chest discomfort requiring emergency intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>UBC Centre for Disease Control, Vancouver, BC. danuta.skowronski@bccdc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kendall</LastName><ForeName>Perry</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>Gaston</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="N">Eye Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12406942</ArticleId><ArticleId IdType="pmc">PMC128396</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Can Commun Dis Rep. 2001 Jan 15;27:1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11227823</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2001 Nov 15;27:1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11817153</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Jun 21;20(21-22):2713-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12034097</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2002 Sep 1;28(ACS-6):1</Citation><ArticleIdList><ArticleId IdType="pubmed">12219587</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 1996 Nov;11(11):673-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9120653</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1999 Apr 9;17(15-16):1898-904</Citation><ArticleIdList><ArticleId IdType="pubmed">10217587</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Excell Nurse Pract. 1999 Mar;3(2):97-104</Citation><ArticleIdList><ArticleId IdType="pubmed">10646398</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2000 Dec 1;26(23):201-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11149349</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2001 May 15;27(10):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11396047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2001 Sep 14;19(32):4760-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11535327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><name sortKey="Duval, Bernard" sort="Duval, Bernard" uniqKey="Duval B" first="Bernard" last="Duval">Bernard Duval</name><name sortKey="Kendall, Perry" sort="Kendall, Perry" uniqKey="Kendall P" first="Perry" last="Kendall">Perry Kendall</name><name sortKey="Strauss, Barbara" sort="Strauss, Barbara" uniqKey="Strauss B" first="Barbara" last="Strauss">Barbara Strauss</name></noCountry><country name="Canada"><noRegion><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000968 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000968 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12406942
|texte= Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12406942" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |